PMID- 37511409
OWN - NLM
STAT- MEDLINE
DCOM- 20230803
LR  - 20230803
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 14
DP  - 2023 Jul 19
TI  - Bradykinin Metabolism and Drug-Induced Angioedema.
LID - 10.3390/ijms241411649 [doi]
LID - 11649
AB  - Bradykinin (BK) metabolism and its receptors play a central role in drug-induced 
      angioedema (AE) without urticaria through increased vascular permeability. Many 
      cardiovascular and diabetic drugs may cause BK-mediated AE. 
      Angiotensin-converting enzyme inhibitors (ACEIs) and neprilysin inhibitors impair 
      BK catabolism. Dipeptidyl peptidase-IV (DPP-IV) inhibitors reduce the breakdown 
      of BK and substance P (SP). Moreover, angiotensin receptor blockers, thrombolytic 
      agents, and statins may also induce BK-mediated AE. Understanding 
      pathophysiological mechanisms is crucial for preventing and treating drug-induced 
      AE.
FAU - Smolinska, Sylwia
AU  - Smolinska S
AUID- ORCID: 0000-0001-6736-2696
AD  - Department of Clinical Immunology, Wroclaw Medical University, 50-368 Wroclaw, 
      Poland.
FAU - Antolin-Amerigo, Dario
AU  - Antolin-Amerigo D
AD  - Servicio de Alergia, Hospital Universitario Ramon y Cajal, Instituto Ramon y 
      Cajal de Investigacion Sanitaria (IRYCIS), 28034 Madrid, Spain.
FAU - Popescu, Florin-Dan
AU  - Popescu FD
AUID- ORCID: 0000-0001-6316-3155
AD  - Department of Allergology "Nicolae Malaxa" Clinical Hospital, "Carol Davila" 
      University of Medicine and Pharmacy, 022441 Bucharest, Romania.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230719
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - S8TIM42R2W (Bradykinin)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Fibrinolytic Agents)
SB  - IM
MH  - Humans
MH  - *Angioedema/chemically induced
MH  - Angiotensin Receptor Antagonists
MH  - Angiotensin-Converting Enzyme Inhibitors/adverse effects
MH  - Bradykinin/metabolism
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - Fibrinolytic Agents/therapeutic use
PMC - PMC10380452
OTO - NOTNLM
OT  - bradykinin metabolism
OT  - drug-induced angioedema
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/29 11:46
MHDA- 2023/07/31 06:43
PMCR- 2023/07/19
CRDT- 2023/07/29 01:24
PHST- 2023/06/23 00:00 [received]
PHST- 2023/07/10 00:00 [revised]
PHST- 2023/07/14 00:00 [accepted]
PHST- 2023/07/31 06:43 [medline]
PHST- 2023/07/29 11:46 [pubmed]
PHST- 2023/07/29 01:24 [entrez]
PHST- 2023/07/19 00:00 [pmc-release]
AID - ijms241411649 [pii]
AID - ijms-24-11649 [pii]
AID - 10.3390/ijms241411649 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Jul 19;24(14):11649. doi: 10.3390/ijms241411649.